Clinical benefits of selumetinib in adults with neurofibromatosis type 1

Suyin Feng, Hua Li, Runfeng Sun

Open source

DOI: 10.1016/s0140-6736(25)02111-7
Published: 2025-12
Container: The Lancet
Publisher: Elsevier BV
Open access: unknown

Credibility signals

uncertain Score 64/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

supportingDOI registered: A matching record was returned by Crossref. Source: Crossref; license: CC0 metadata
supportingDOI resolves: A matching record was returned by Crossref. Source: Crossref; license: CC0 metadata
not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredOpen access status: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
supportingMetadata completeness: All 6 scored descriptive metadata groups are present. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.1016/s0140-6736-25-02111-7,
  title = {Clinical benefits of selumetinib in adults with neurofibromatosis type 1},
  author = {Suyin Feng and Hua Li and Runfeng Sun},
  year = {2025},
  journal = {The Lancet},
  doi = {10.1016/s0140-6736(25)02111-7},
  url = {https://doi.org/10.1016/s0140-6736(25)02111-7}
}

RIS

TY  - JOUR
TI  - Clinical benefits of selumetinib in adults with neurofibromatosis type 1
AU  - Suyin Feng
AU  - Hua Li
AU  - Runfeng Sun
PY  - 2025
JO  - The Lancet
DO  - 10.1016/s0140-6736(25)02111-7
UR  - https://doi.org/10.1016/s0140-6736(25)02111-7
ER  -

APA

Feng, S., Li, H., & Sun, R. (2025). Clinical benefits of selumetinib in adults with neurofibromatosis type 1. The Lancet. https://doi.org/10.1016/s0140-6736(25)02111-7

Source records

crossref · retrieved 2026-09-27T02:48:39.871Z